APA (7th ed.) Citation

Jinhua, L., Li, W., Xiaodong, W., Guohui, C., Jianfeng, Z., Tongyao, X., . . . Wei, X. (2024). Chidamide plus prednisone, cyclophosphamide, and thalidomide for relapsed or refractory peripheral T-cell lymphoma: A multicenter phase II trial. 中华医学杂志英文版, 137(13), 1576-1582. https://doi.org/10.1097/CM9.0000000000002836

Chicago Style (17th ed.) Citation

Jinhua, Liang, et al. "Chidamide Plus Prednisone, Cyclophosphamide, and Thalidomide for Relapsed or Refractory Peripheral T-cell Lymphoma: A Multicenter Phase II Trial." 中华医学杂志英文版 137, no. 13 (2024): 1576-1582. https://doi.org/10.1097/CM9.0000000000002836.

MLA (9th ed.) Citation

Jinhua, Liang, et al. "Chidamide Plus Prednisone, Cyclophosphamide, and Thalidomide for Relapsed or Refractory Peripheral T-cell Lymphoma: A Multicenter Phase II Trial." 中华医学杂志英文版, vol. 137, no. 13, 2024, pp. 1576-1582, https://doi.org/10.1097/CM9.0000000000002836.